Annual CFF
$7.02 M
-$18.27 M-72.24%
December 31, 2023
Summary
- As of February 8, 2025, AKTX annual cash flow from financing activities is $7.02 million, with the most recent change of -$18.27 million (-72.24%) on December 31, 2023.
- During the last 3 years, AKTX annual CFF has fallen by -$18.05 million (-72.00%).
- AKTX annual CFF is now -89.83% below its all-time high of $69.04 million, reached on December 31, 2015.
Performance
AKTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$443.00 K
-$8.21 M-105.71%
September 1, 2024
Summary
- As of February 8, 2025, AKTX quarterly cash flow from financing activities is -$443.00 thousand, with the most recent change of -$8.21 million (-105.71%) on September 1, 2024.
- Over the past year, AKTX quarterly CFF has dropped by -$8.21 million (-105.71%).
- AKTX quarterly CFF is now -100.61% below its all-time high of $72.61 million, reached on September 30, 2015.
Performance
AKTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$12.35 M
-$443.00 K-3.46%
September 1, 2024
Summary
- As of February 8, 2025, AKTX TTM cash flow from financing activities is $12.35 million, with the most recent change of -$443.00 thousand (-3.46%) on September 1, 2024.
- Over the past year, AKTX TTM CFF has dropped by -$443.00 thousand (-3.46%).
- AKTX TTM CFF is now -83.75% below its all-time high of $76.00 million, reached on September 30, 2015.
Performance
AKTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
AKTX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -72.2% | -105.7% | -3.5% |
| 3 y3 years | -72.0% | -104.0% | -35.6% |
| 5 y5 years | +1304.0% | -105.3% | -2.4% |
AKTX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -72.2% | at low | -103.6% | at low | -53.7% | +284.5% |
| 5 y | 5-year | -72.2% | at low | -103.6% | at low | -59.2% | +284.5% |
| alltime | all time | -89.8% | -100.0% | -100.6% | +94.4% | -83.8% | +374.9% |
Akari Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$443.00 K(-105.7%) | $12.35 M(-3.5%) |
| Jun 2024 | - | $7.76 M(+412.7%) | $12.79 M(+140.4%) |
| Mar 2024 | - | $1.51 M(-57.0%) | $5.32 M(-24.2%) |
| Dec 2023 | $7.02 M(-72.2%) | $3.52 M(>+9900.0%) | $7.02 M(+100.4%) |
| Sep 2023 | - | $0.00(-100.0%) | $3.50 M(0.0%) |
| Jun 2023 | - | $291.00 K(-90.9%) | $3.50 M(+9.1%) |
| Mar 2023 | - | $3.21 M(>+9900.0%) | $3.21 M(-87.0%) |
| Dec 2022 | $25.29 M(+76.9%) | - | - |
| Jun 2022 | - | $0.00(-100.0%) | $24.67 M(-7.5%) |
| Mar 2022 | - | $12.37 M(+1007.7%) | $26.66 M(+86.5%) |
| Dec 2021 | $14.29 M(-43.0%) | $1.12 M(-90.0%) | $14.29 M(-25.4%) |
| Sep 2021 | - | $11.18 M(+461.0%) | $19.17 M(+140.0%) |
| Jun 2021 | - | $1.99 M(>+9900.0%) | $7.99 M(-47.4%) |
| Mar 2021 | - | $0.00(-100.0%) | $15.20 M(-39.4%) |
| Dec 2020 | $25.07 M(+98.2%) | $5.99 M(>+9900.0%) | $25.07 M(+14.7%) |
| Sep 2020 | - | $0.00(-100.0%) | $21.86 M(-27.8%) |
| Jun 2020 | - | $9.20 M(-6.8%) | $30.26 M(+35.3%) |
| Mar 2020 | - | $9.88 M(+255.8%) | $22.37 M(+76.9%) |
| Dec 2019 | $12.65 M | $2.78 M(-66.9%) | $12.65 M(+26.2%) |
| Sep 2019 | - | $8.40 M(+538.1%) | $10.03 M(+407.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2019 | - | $1.32 M(+734.6%) | $1.97 M(+200.1%) |
| Mar 2019 | - | $157.70 K(+2.8%) | $657.70 K(+31.5%) |
| Dec 2018 | $500.00 K(-96.8%) | $153.40 K(-55.7%) | $500.00 K(-96.9%) |
| Sep 2018 | - | $346.60 K(>+9900.0%) | $16.02 M(+2.2%) |
| Jun 2018 | - | $0.00(0.0%) | $15.67 M(0.0%) |
| Mar 2018 | - | $0.00(-100.0%) | $15.67 M(0.0%) |
| Dec 2017 | $15.67 M(>+9900.0%) | $15.67 M(>+9900.0%) | $15.67 M(>+9900.0%) |
| Sep 2017 | - | $0.00(-100.0%) | $0.00(-100.0%) |
| Dec 2016 | $0.00(-100.0%) | - | - |
| Dec 2015 | $69.04 M(+1530.2%) | -$3.06 M(-104.2%) | $69.04 M(-9.1%) |
| Sep 2015 | - | $72.61 M(<-9900.0%) | $76.00 M(-1791.7%) |
| Jun 2015 | - | -$508.70 K(-113.1%) | -$4.49 M(-206.1%) |
| Dec 2014 | $4.24 M(-64.7%) | $3.89 M(-149.4%) | $4.24 M(+1137.7%) |
| Sep 2014 | - | -$7.88 M(<-9900.0%) | $342.20 K(-95.8%) |
| Jun 2014 | - | $0.00(-100.0%) | $8.22 M(0.0%) |
| Mar 2014 | - | $8.22 M | $8.22 M |
| Dec 2013 | $12.00 M(+271.4%) | - | - |
| Dec 2012 | $3.23 M(+221.6%) | - | - |
| Dec 2011 | $1.00 M(+170.2%) | - | - |
| Dec 2010 | $372.00 K | - | - |
FAQ
- What is Akari Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Akari Therapeutics?
- What is Akari Therapeutics annual CFF year-on-year change?
- What is Akari Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Akari Therapeutics?
- What is Akari Therapeutics quarterly CFF year-on-year change?
- What is Akari Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Akari Therapeutics?
- What is Akari Therapeutics TTM CFF year-on-year change?
What is Akari Therapeutics annual cash flow from financing activities?
The current annual CFF of AKTX is $7.02 M
What is the all time high annual CFF for Akari Therapeutics?
Akari Therapeutics all-time high annual cash flow from financing activities is $69.04 M
What is Akari Therapeutics annual CFF year-on-year change?
Over the past year, AKTX annual cash flow from financing activities has changed by -$18.27 M (-72.24%)
What is Akari Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of AKTX is -$443.00 K
What is the all time high quarterly CFF for Akari Therapeutics?
Akari Therapeutics all-time high quarterly cash flow from financing activities is $72.61 M
What is Akari Therapeutics quarterly CFF year-on-year change?
Over the past year, AKTX quarterly cash flow from financing activities has changed by -$8.21 M (-105.71%)
What is Akari Therapeutics TTM cash flow from financing activities?
The current TTM CFF of AKTX is $12.35 M
What is the all time high TTM CFF for Akari Therapeutics?
Akari Therapeutics all-time high TTM cash flow from financing activities is $76.00 M
What is Akari Therapeutics TTM CFF year-on-year change?
Over the past year, AKTX TTM cash flow from financing activities has changed by -$443.00 K (-3.46%)